Table 1.
Recoveryb | |||||
---|---|---|---|---|---|
Study | Disease | Cytotoxic therapy | Hormone treatment | Hormone-treated | Controls |
Johnson et al., 1985 | Hodgkin’s | MOPP 3–6 cycles | GnRH agonist | 1 of 5 | No controls |
Waxman et al., 1987 | Hodgkin’s | MVPP, ChlVPP | GnRH agonist + testosterone | 0 of 20 | 0 of 10 |
Redman & Bajorunas, 1987 | Hodgkin’s | MOPP ~4 cycles | Testosterone | ≈70% of 23c | ≈70% of 22c |
Fossa et al., 1988 | Testis Ca | PVB, ADR/CY, Radiation | Medroxy-progesterone | 0 of 4 (2 of 12)d | 2 of 3 (7 of 13)d |
Kreuser et al., 1990 | Testis Ca | PVB | GnRH agonist | 6 of 6 | 8 of 8 |
Brennemann et al., 1994 | Testis Ca (Seminoma) | Radiation | GnRH agonist + antiandrogen | 12 of 12 | 8 of 8 |
Masala et al., 1997 | Nephritis | Cyclophosphamide | Testosterone | 5 of 5 | 1 of 5 |
Chemotherapy regimens are as follows: MOPP, mechlorethamine, vincristine, procarbazine; and prednisone; MVPP, mechlorethamine, vinblastine, procarbazine, and prednisone; ChlVPP, chlorambucil, vinblastine, procarbazine, and prednisone; PVB: cisplatin, vinblastine, bleomycin; ADR/CY: Adriamycin, cyclophosphamide.
Fraction of men recovering testicular function as assessed by restoration of sperm counts to normospermic levels unless otherwise noted.
Actuarial recovery calculated by Kaplan-Meier analysis
Recovery assessed by restoration of FSH levels to within the normal control range.